SS Innovations International, Inc. (Nasdaq: SSII), a developer of surgical robotic technologies, announced today that more than 10,500 cumulative surgeries have been successfully performed with its SSi Mantra surgical robotic system as of April 30, 2026. This milestone includes over 500 cardiac procedures, 170 telesurgeries, and 125 pediatric surgeries, with approximately 2,100 physicians trained on the system across more than 170 different types of procedures.
Since the commercial launch of the SSi Mantra in August 2022, the company has expanded its global installed base to more than 200 systems across eleven countries, with a strong presence in the Indian market. Dr. Sudhir Srivastava, Chairman and CEO of SS Innovations, attributed the rapid adoption to the system's advanced technology, ease of training, user-friendliness, and cost advantages. He stated, “Reaching 10,500 cumulative surgeries in such a short time span reflects the SSi Mantra’s advanced technology, differentiated features, ease of training, user-friendliness, and clear cost advantages.”
The SSi Mantra is a modular, multi-arm system featuring 3 to 5 robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and a virtual real-time image of the robotic patient side arm carts. It supports over 40 types of robotic endo-surgical instruments, including 5mm instruments for pediatric and ENT surgeries. The optional SSi MantrAsana Tele Surgeon Console allows for enhanced portability and telesurgery capability. The system has been clinically validated in India in more than 100 different surgical procedures.
This achievement underscores the growing trust in the SSi Mantra among healthcare institutions and surgeons globally. The company’s vision is to make robotic surgery affordable and accessible worldwide. For more information, visit the company’s website at ssinnovations.com or follow updates on LinkedIn. The latest news and updates relating to $SSII are available in the company’s newsroom at https://tinyurl.com/ssiinewsroom.
